JP2013521233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521233A5 JP2013521233A5 JP2012555201A JP2012555201A JP2013521233A5 JP 2013521233 A5 JP2013521233 A5 JP 2013521233A5 JP 2012555201 A JP2012555201 A JP 2012555201A JP 2012555201 A JP2012555201 A JP 2012555201A JP 2013521233 A5 JP2013521233 A5 JP 2013521233A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- group
- patient
- immunotherapy targeting
- pet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 75
- 239000003446 ligand Substances 0.000 claims 28
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 238000009169 immunotherapy Methods 0.000 claims 25
- 230000008685 targeting Effects 0.000 claims 24
- 230000003941 amyloidogenesis Effects 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 210000004556 brain Anatomy 0.000 claims 16
- 229910052740 iodine Inorganic materials 0.000 claims 9
- 208000037259 Amyloid Plaque Diseases 0.000 claims 8
- 238000005259 measurement Methods 0.000 claims 8
- 238000012544 monitoring process Methods 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- 229950001863 bapineuzumab Drugs 0.000 claims 7
- 229910052794 bromium Inorganic materials 0.000 claims 7
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000000902 placebo Substances 0.000 claims 6
- 229940068196 placebo Drugs 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 230000007423 decrease Effects 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 5
- 230000004044 response Effects 0.000 claims 5
- 150000003384 small molecules Chemical class 0.000 claims 5
- 230000000977 initiatory effect Effects 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 230000003920 cognitive function Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- CEGXZKXILQSJHO-KODRXGBYSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanoyl fluoride Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC(F)=O CEGXZKXILQSJHO-KODRXGBYSA-N 0.000 claims 1
- IAVCEBMLYVGBLA-UHFFFAOYSA-N 2-[1-[6-[2-fluoroethyl(methyl)amino]naphthalen-2-yl]ethylidene]propanedinitrile Chemical compound C1=C(C(C)=C(C#N)C#N)C=CC2=CC(N(CCF)C)=CC=C21 IAVCEBMLYVGBLA-UHFFFAOYSA-N 0.000 claims 1
- MYNQXTDIPMCJCR-HUYCHCPVSA-N 2-[2-fluoranyl-6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol Chemical compound [18F]C1=NC(NC)=CC=C1C1=CC2=CC(O)=CC=C2O1 MYNQXTDIPMCJCR-HUYCHCPVSA-N 0.000 claims 1
- -1 4-methylpiperidinyl ring Chemical group 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 229910052793 cadmium Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 238000011161 development Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 229940009600 gammagard Drugs 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000006872 improvement Effects 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000011418 maintenance treatment Methods 0.000 claims 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 210000000869 occipital lobe Anatomy 0.000 claims 1
- 210000001152 parietal lobe Anatomy 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- PUZPDOWCWNUUKD-ULWFUOSBSA-M sodium;fluorine-18(1-) Chemical compound [18F-].[Na+] PUZPDOWCWNUUKD-ULWFUOSBSA-M 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 210000003478 temporal lobe Anatomy 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30825310P | 2010-02-25 | 2010-02-25 | |
| US61/308,253 | 2010-02-25 | ||
| PCT/US2011/026365 WO2011106732A1 (en) | 2010-02-25 | 2011-02-25 | Pet monitoring of ab-directed immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016093421A Division JP2016185964A (ja) | 2010-02-25 | 2016-05-06 | Ａβを標的とする免疫療法のＰＥＴモニタリング |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013521233A JP2013521233A (ja) | 2013-06-10 |
| JP2013521233A5 true JP2013521233A5 (enExample) | 2014-09-25 |
Family
ID=44507245
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555201A Pending JP2013521233A (ja) | 2010-02-25 | 2011-02-25 | Ａβを標的とする免疫療法のＰＥＴモニタリング |
| JP2016093421A Pending JP2016185964A (ja) | 2010-02-25 | 2016-05-06 | Ａβを標的とする免疫療法のＰＥＴモニタリング |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016093421A Pending JP2016185964A (ja) | 2010-02-25 | 2016-05-06 | Ａβを標的とする免疫療法のＰＥＴモニタリング |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130084245A1 (enExample) |
| EP (1) | EP2538982A4 (enExample) |
| JP (2) | JP2013521233A (enExample) |
| WO (1) | WO2011106732A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| PL2579042T3 (pl) * | 2011-10-04 | 2014-12-31 | Affiris Ag | Sposób wykrywania przeciwciał swoistych wobec Aß w próbce biologicznej |
| IN2014CN03661A (enExample) | 2011-11-16 | 2015-10-16 | Koninkl Philips Nv | |
| JP2015526409A (ja) * | 2012-07-03 | 2015-09-10 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｃ−末端及び中心エピトープａ−ベータ抗体 |
| CN106831799B (zh) * | 2016-12-20 | 2018-12-21 | 四川大学 | 羟基苯乙烯吡啶曼尼希碱类化合物、其制备方法和用途 |
| KR102031652B1 (ko) * | 2018-01-19 | 2019-10-14 | 서울대학교산학협력단 | 전이체 단백질 과발현 관련 질환의 양성자방출단층촬영 방사성추적자, 형광영상 진단 및 광역학 치료를 위한 전이체 단백질 표적 리간드 및 이의 제조방법 |
| EP3759121A1 (en) | 2018-03-01 | 2021-01-06 | Trigemina, Inc. | Labeled oxytocin and method of manufacture and use |
| IL280315B2 (en) * | 2018-07-24 | 2024-06-01 | Eisai R&D Man Co Ltd | Methods for treating and preventing Alzheimer's disease |
| EP3840652B1 (en) * | 2018-08-21 | 2024-02-28 | Koninklijke Philips N.V. | Method and apparatus for amyloid screening |
| EP4073113A4 (en) * | 2019-12-11 | 2024-02-14 | Ambetex Pty Ltd | THERAPEUTIC COMPOSITIONS COMPRISING A BETA-AMYLOID ANTIBODY OR A VACCINE FOR THE PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE344803T1 (de) | 1999-12-08 | 2006-11-15 | Intellect Neurosciences Inc | Schimärische amyloid-beta peptide |
| EP1296705B1 (en) | 2000-06-28 | 2012-06-13 | Prana Biotechnology Limited | Amyloid Beta oligomers for use in treatment, alleviation or prevention of Alzheimer's Disease |
| JP5362164B2 (ja) | 2000-07-07 | 2013-12-11 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病の予防及び治療 |
| US6395837B1 (en) | 2000-08-03 | 2002-05-28 | King Industries, Inc. | Alkylated aryl disulfonic acid catalysts for crosslinking polyethylene |
| PT1524994E (pt) | 2002-07-19 | 2011-08-01 | Cytos Biotechnology Ag | Composições de vacina contendo fileiras de antigénio amilóide beta 1-6 |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US20040242845A1 (en) | 2003-02-21 | 2004-12-02 | Nicolau Yves Claude | Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them |
| WO2005012330A2 (en) | 2003-07-30 | 2005-02-10 | Brigham And Women's Hospital, Inc. | AMYLOID β-PEPTIDE AND METHODS OF USE |
| US20050214222A1 (en) * | 2004-02-13 | 2005-09-29 | Mckinnon Stuart J | In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes |
| US8147798B2 (en) * | 2004-07-02 | 2012-04-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies |
| AT413946B (de) | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| BRPI0610093A2 (pt) | 2005-05-05 | 2008-12-09 | Merck & Co Inc | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente |
| WO2009017467A1 (en) * | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| JP2010521651A (ja) * | 2007-03-12 | 2010-06-24 | 独立行政法人放射線医学総合研究所 | 脳内のアミロイド関連神経炎症の画像化 |
| BRPI0810118A8 (pt) * | 2007-04-18 | 2015-09-29 | Janssen Alzheimer Immunotherap | Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
-
2011
- 2011-02-25 WO PCT/US2011/026365 patent/WO2011106732A1/en not_active Ceased
- 2011-02-25 JP JP2012555201A patent/JP2013521233A/ja active Pending
- 2011-02-25 EP EP11748201.8A patent/EP2538982A4/en not_active Withdrawn
- 2011-02-25 US US13/580,866 patent/US20130084245A1/en not_active Abandoned
-
2016
- 2016-05-06 JP JP2016093421A patent/JP2016185964A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521233A5 (enExample) | ||
| Lobello et al. | Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer′ s Disease | |
| JP2025182058A (ja) | アルツハイマー病の治療法 | |
| AU2019264073B2 (en) | 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting ASM activity, and use thereof | |
| Berk et al. | Successes and failures for drugs in late-stage development for Alzheimer’s disease | |
| US20130084245A1 (en) | Pet monitoring of a-beta-directed immunotherapy | |
| JP2022145965A (ja) | アルツハイマー病を治療する方法 | |
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| Maya et al. | Novel radioiodinated aurones as probes for SPECT imaging of β-amyloid plaques in the brain | |
| JP2015526409A5 (enExample) | ||
| US20190282714A1 (en) | Radioligands for imaging the ido1 enzyme | |
| CA3211944A1 (en) | Anti-amyloid beta antibodies and uses thereof | |
| TW202231661A (zh) | 安全投予抗ｔａｕ抗體之方法 | |
| CA2966582A1 (en) | Low dosage a2a antagonist for the treatment of adhd and parkinsons | |
| US9180212B2 (en) | β-amyloid plaque imaging agents | |
| JP2013237655A (ja) | コンフォメーション病診断用分子プローブ | |
| KR20250078929A (ko) | 알츠하이머병 치료를 위한 면역치료법과 사일로이노시톨 병용 | |
| Loureiro et al. | New Perspectives for Treatment in Alzheimer’s Disease | |
| Ferrer et al. | Towards early detection and treatment of Alzheimer’s disease | |
| Furumoto et al. | Synthesis and Preclinical Evaluation of a Fluorine-18 Labeled BF-227 Derivative |